May 20, 2013
Takeda Pharmaceutical announced on May 16 that its novel type 2 diabetes treatment fasiglifam (development code: TAK-875), a GPR40 agonist, showed a statistically significant effect in lowering blood-sugar levels compared to placebo, according to the results of the PIII CCT-003...read more